Two New Treatments for Gonorrhea; one is available now!

In this episode of the Conversations with CEI, infectious disease specialist Dr. Steven Fine delves into groundbreaking advancements in the treatment of urogenital gonorrhea. The episode highlights the FDA's December 2025 approval of two innovative oral therapies that mark a significant step forward in combating this prevalent sexually transmitted infection.

Dr. Fine discusses the first of these treatments, Zoliflodacin (Nuzolvence), a novel medication specifically developed for urogenital gonorrhea. Administered as a single oral dose, it offers patients a convenient and effective option. The second treatment, Gepotidacin (Blujepa), is a versatile drug initially approved in March 2025 for urinary tract infections (UTIs). Now, it has been authorized for urogenital gonorrhea treatment, requiring two oral doses for optimal efficacy.

Throughout the episode, Dr. Fine provides insights into the clinical trials, mechanisms of action, and potential impact of these therapies on public health. He also emphasizes the importance of addressing antibiotic resistance in gonorrhea and how these new treatments may help mitigate this growing concern.

For more information, listeners can refer to the FDA's official announcement and other resources provided below.

Tune in to this episode to learn more about these exciting developments and their implications for the future of infectious disease treatment. Related Content:

FDA Approves Two Oral Therapies to Treat Gonorrhea https://www.fda.gov/news-events/press-announcements/fda-approves-two-oral-therapies-treat- gonorrhea
CEI Clinical Consultation Line 1-866-637-2342 A toll-free service for NYS clinicians offering real-time clinical consultations with specialists on HIV, sexual health, hepatitis C, and drug user health.
https://ceitraining.org/

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(63)

Recap of the 2025 Annual New York State Hepatitis C and Drug User Health Conference

On September 9th, CEI hosted its first in-person conference dedicated to hepatitis C and drug user health. A group of New York State-based clinicians met in Catskill for a full day agenda focused on (...

9 Loka 202527min

Insights from the 13th International AIDS Society Conference on HIV Science

In this episode of Conversations with CEI, Dr. Steven Fine unpacks some of the latest developments and research presented at the 2025 International AIDS Society (IAS) Conference on HIV Science, held i...

9 Syys 202516min

Evolving Landscape of Geriatric HIV Care

The demographics of HIV care are rapidly changing, and with them, the clinical needs of patients aging with HIV. In this episode, host Dr. Tony Urbina, Medical Director for CEI's HIV Primary Care and ...

11 Elo 202527min

Highlights and Perspectives from the 11th Annual NYS Sexual Health Conference

Live from Canandaigua…it’s the 11th Annual NYS Sexual Health Conference! The CEI Sexual Health Center of Excellence hosted the 11th Annual NYS Sexual Health Conference in-person on Friday May 2, 2025,...

10 Heinä 202516min

Xylazine & Medetomidine & Nitazines, Oh My! An Update on New York State’s Drug Supply

New York drug overdose deaths and death rates are on the decline, but with significant disparities and the current, toxic drug supply is partially to blame. Harmful additives like fentanyl analogues, ...

12 Kesä 202529min

CEI…we got you! Evolving with the Science

In this episode of Conversations with CEI, we engage with CEI’s clinicians, researchers, and public health experts to explore current and emerging issues in HIV primary care, sexual health, Hepatitis ...

16 Touko 202538min

Navigating Measles Vaccine Recommendations for Patients with HIV

In light of the increase in measles cases within the United States, this episode features Dr. Steven Fine, an infectious disease expert, who offers a comprehensive exploration of the history and progr...

8 Touko 202520min

The Invisible Latino HIV Crisis

In May 2024, the Centers for Disease Control and Prevention (CDC) released its annual HIV surveillance reports. The new data show a continuation of year-over-year reductions through 2022 in the estima...

10 Huhti 202521min